Lenvatinib/Pembrolizumab Improves Survival in Renal Cell Carcinoma

Results from a phase 3 trial of patients with advanced renal cell carcinoma (RCC) presented this week at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium and simultaneously published in The New England Journal of Medicine demonstrated that the first-line treatment regimen of lenvatinib, a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor, plus pembrolizumab, an anti–programmed cell death protein 1 (PD-1) monoclonal antibody, lengthened ...
Continue reading

Tepotinib Approved for Metastatic MET-Altered Non-Small Cell Lung Cancer

The FDA has granted accelerated approval to tepotinib (Tepmetko®, EMD Serono) for patients with metastatic non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping alterations. "A splice-site mutation that results in a loss of transcription of exon 14 in the oncogenic driver MET occurs in 3% to 4% of patients with NSCLC," wrote the investigators of the phase 2 VISION trial (NCT02864992) in their September publication in The New England Journal of Medicine,...
Continue reading

Companion Diagnostic Approved to Identify NTRK Fusions in Patients Eligible for Larotrectinib

The FDA has approved FoundationOne® CDx (Foundation Medicine, Inc.) as a companion diagnostic device to identify neurotrophic receptor tyrosine kinase (NTRK) fusions in patients with solid tumors in order to determine eligibility for treatment with larotrectinib (Vitrakvi®, Bayer Healthcare Pharmaceuticals, Inc.). FoundationOne is a next-generation sequencing (NGS)-based in vitro diagnostic device previously approved to determine eligibility for more than 20 other FDA-approved targeted therapies...
Continue reading

Geriatric and Surgical Comanagement for Older Patients With Cancer: Armin Shahrokni, MD, MPH

Patients aged 75 years and older face an increased risk of mortality and postoperative events when undergoing surgical treatment for cancer. In a study recently published in JAMA Network Open, a research team led by first author Armin Shahrokni, MD, MPH, found that patients whose care was managed by both the surgical and geriatric teams experienced significantly better outcomes compared with those whose care was provided by the surgical team alone. In this interview with i3 Health, Dr. Shahrokni...
Continue reading

Tafasitamab/Lenalidomide for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Gilles Salles, MD, PhD

Recently, the FDA granted accelerated approval to tafasitamab-cxix (Monjuvi®, MorphoSys US Inc.) in combination with lenalidomide for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplantation. In this interview with i3 Health, Gilles Salles, MD, PhD, principal investigator of the phase 2 L-MIND trial, on which the approval was based, discusses the significance of the approval, adverse events of note with tafasitamab/lenal...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.

Cron Job Starts